In addition to CD33, potential targets identified by proteomic and transcriptomic studies of myeloid cell lines and AML samples include CD123, CD96, CD44, CD47, CD32, CLL‐1, IL1RAP, TIM‐3, and LILRB4 (Dobrowolska et al., 2013; Gasiorowski et al., 2014; Mardis, 2014; Strassberger et al., 2014). This evidence concerns the gene CD96 and acute myeloid leukemia.